Get the Stockscreener App
257.06
1.79%
4.53
After Hours:
256.98
-0.08
-0.03%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $257.06, with a volume of 924.54K.
It is up +1.79% in the last 24 hours and up +0.62% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$252.53
Open:
$254.18
24h Volume:
924.54K
Relative Volume:
0.90
Market Cap:
$37.45B
Revenue:
$5.40B
Net Income/Loss:
$1.49B
P/E Ratio:
25.41
EPS:
10.1168
Net Cash Flow:
$1.78B
1W Performance:
+0.30%
1M Performance:
+0.62%
6M Performance:
-9.86%
1Y Performance:
+9.57%
1-Day Range:
$253.58
$258.24
1-Week Range:
$250.19
$261.91
52-Week Range:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
257.06 | 36.79B | 5.40B | 1.49B | 1.78B | 10.12 |
|
ISRG
Intuitive Surgical Inc
|
506.88 | 179.76B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
176.66 | 51.48B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
86.72 | 42.38B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
48.89 | 39.09B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Dakota Wealth Management Grows Stake in ResMed Inc. $RMD - MarketBeat
Is ResMed Stock A Trap Or A Missed Opportunity? - Trefis
Why I would buy ResMed and these quality blue chips now - The Motley Fool Australia
Is ResMed Stock Poised for a Rally? - Trefis
Shares of Resmed Fall 3% After Declaring Plan to Open New US Distribution Center - marketscreener.com
Resmed to open new distribution center in Indiana - MassDevice
ResMed Greenwood Hub Aims To Tighten Logistics And Support Growth - simplywall.st
Braun: Resmed to build $30 million facility in Greenwood - Fox 59
ResMed Inc (RMD) Shares Gap Down to $251.69 on Feb 24 - GuruFocus
ResMed opens new distribution center in Greenwood, Indiana - TipRanks
Resmed (RMD) Expands U.S. Footprint with New Indiana Distributio - GuruFocus
ResMed to Open New Distribution Center in Indiana - marketscreener.com
ResMed expands US operations with new distribution center in Indiana - marketscreener.com
Resmed Expands U.S. Operations With New Distribution Center in Greenwood, Indiana - 富途牛牛
LGT Capital Partners LTD. Decreases Stock Position in ResMed Inc. $RMD - MarketBeat
Anti-snoring Devices Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations and Launches, Sustainability Goals, Revenue Insights - GlobeNewswire Inc.
Washington Trust Advisors Inc. Lowers Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Emerges as a Prime Quality Investing Candidate - ChartMill
Resmed Founder to Receive Prestigious Award - Sleep Review
NEOS Investment Management LLC Has $3.71 Million Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
ResMed Narrowing Search for U.S. Device Manufacturing Site -- Interview - 富途牛牛
Sleep Aids: Trends, Technologies and Global Markets to 2030 Featuring Key Players Fisher & Paykel Healthcare, ResMed, Philips, Alphabet, Apple and More - Yahoo Finance UK
Stock Recap: Is ResMed Inc stock showing strong momentumEarnings Recap Report & High Yield Equity Trading Tips - baoquankhu1.vn
ResMed Stock Outlook: Is Wall Street Bullish or Bearish? - Barchart.com
Skandinaviska Enskilda Banken AB publ Has $23.55 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
Vanguard Group Inc. Acquires 293,515 Shares of ResMed Inc. $RMD - MarketBeat
W.G. Shaheen & Associates DBA Whitney & Co Sells 4,003 Shares of ResMed Inc. $RMD - MarketBeat
Aug Action: How volatile is ResMed Inc stockJuly 2025 Big Picture & AI Powered Market Trend Analysis - baoquankhu1.vn
ResMed Inc. $RMD Shares Sold by ABN Amro Investment Solutions - MarketBeat
ResMed Inc. (RMD) Stock Analysis: Evaluating A 17.79% Potential Upside For Investors - DirectorsTalk Interviews
ResMed Inc Announces Changes in Beneficial Ownership - MSN
If EPS Growth Is Important To You, ResMed (NYSE:RMD) Presents An Opportunity - Yahoo Finance
Aberdeen Group plc Has $75.94 Million Stake in ResMed Inc. $RMD - MarketBeat
ResMed (RMD): Buy, Sell, or Hold Post Q4 Earnings? - Finviz
ResMed Inc. (RMD) Gains Analyst Confidence as Price Targets Rise on Strong Earnings - Insider Monkey
Why is the ResMed share price jumping 7% today? - MSN
Why analysts raise outlook for ResMed Inc. (RME) stockSwing Trade & Smart Money Movement Tracker - mfd.ru
7,172 Shares in ResMed Inc. $RMD Purchased by Caprock Group LLC - MarketBeat
Rhumbline Advisers Boosts Position in ResMed Inc. $RMD - MarketBeat
Envestnet Asset Management Inc. Raises Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CPAP Headgear Market to See Thriving Worldwide | ResMed • Philips Respironics • Fisher & Paykel Healthcare - openPR.com
Dr Boreham’s Crucible: A rival may be circling, but ResMed isn’t losing any sleep - Stockhead
ResMed Tests Smart CPAP Pressure Tool in New Sleep Apnea Trial - TipRanks
ResMed (RMD) Valuation Check After Strong Earnings And Dividend Update - Yahoo Finance
Is It Time To Reassess ResMed (RMD) After Recent Medical Devices Sector Interest - Yahoo Finance
Resmed launches AirTouch F30i Comfort full-face fabric mask - MassDevice
Baader Bank Aktiengesellschaft Sells 8,794 Shares of ResMed Inc. $RMD - MarketBeat
Michael Farrell Sells 4,991 Shares of ResMed (NYSE:RMD) Stock - MarketBeat
Zacks.com featured highlights include Amphenol, GE Aerospace, ResMed and Ameriprise Financial - The Globe and Mail
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.47%
2.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):